Overview

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

Status:
Completed

Trial end date:
2018-01-03

Target enrollment:

Participant gender:

Summary

E2006-A001-108 is a 4-period crossover study designed to demonstrate that the mean change from baseline in postural stability (worsening) when participants are awakened at approximately 4 hours postdose is significantly less after lemborexant than after zolpidem tartrate extended release following a single-dose administration at bedtime.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Purdue Pharma LP

Treatments:

Zolpidem